Association of growth with neurodevelopment in extremely low gestational age infants: a population-based analysis

Roland Gerull1,2, Eva Huber3, Valentin Rousson4

  • 1Department of Neonatology, University Children's Hospital Basel UKBB, University of Basel, 4056, Basel, Switzerland. roland.gerull@ukbb.ch.

Insights

Postnatal growth in extremely low gestational age newborns (ELGAN) did not significantly predict neurodevelopmental outcomes at two years. This suggests growth

Area of Science:

  • Neonatalogy and Developmental Pediatrics
  • Perinatal Medicine
  • Growth and Development Studies

Background:

  • Conflicting results exist regarding the association between postnatal growth and neurodevelopment in extremely low gestational age newborns (ELGAN, <28 weeks' gestation).
  • Previous assumptions may have overestimated the role of postnatal growth as a predictor of neurodevelopmental outcomes in infancy.

Purpose of the Study:

  • To investigate the relationship between postnatal growth trajectories and neurodevelopmental outcomes at two years of age in ELGAN.
  • To determine if growth from birth to hospital discharge or birth to two-year follow-up is associated with neurodevelopmental impairment.

Main Methods:

  • Retrospective population-based cohort study of live-born ELGAN in Switzerland (2006-2012).
  • Growth parameters (weight, length, head circumference, BMI) assessed at birth, discharge, and 2-year follow-up (FU2).
  • Regression models analyzed associations between growth changes and neurodevelopmental indices (mental and psychomotor) at FU2.

Main Results:

  • 1244 ELGAN infants included; 1049 (84.3%) had 2-year follow-up.
  • Moderate/severe neurodevelopmental impairment occurred in 23.2% of infants.
  • No significant association was found between growth parameters (birth to discharge or birth to FU2) and neurodevelopmental outcomes.

Conclusions:

  • Postnatal growth between birth and hospital discharge is not significantly associated with neurodevelopment at two years in ELGAN.
  • Growth from birth to two-year follow-up also showed no significant association with neurodevelopmental outcomes in this cohort.
  • The predictive value of postnatal growth on neurodevelopmental outcomes in ELGAN may be less significant than previously thought.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
20.7K
Neurulation01:30

Neurulation

Neurulation is the embryological process which forms the precursors of the central nervous system and occurs after gastrulation has established the three primary cell layers of the embryo: ectoderm, mesoderm, and endoderm. In humans, the majority of this system is formed via primary neurulation, in which the central portion of the ectoderm—originally appearing as a flat sheet of cells—folds upwards and inwards, sealing off to form a hollow neural tube. As development proceeds, the...
42.3K